# Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Stat

Source: https://onco.cc/trials/nct07595276/  
OnCo record `nct07595276` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of cetuximab in colorectal cancer, run by Taizhou Mabtech Pharmaceutical Co.,Ltd, not yet recruiting.

## Summary

Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status. is a phase 3, randomised interventional study registered as NCT07595276 by Taizhou Mabtech Pharmaceutical Co.,Ltd, with a registry enrolment figure of 608 participants, started 2026-06-01 and due to reach its primary completion in 2029-10-01. Interventions recorded: Enlituo®; Erbitux®. Conditions listed: Colorectal Cancer. Primary outcome: Objective Response Rate (ORR) within 16 weeks assessed by BIRC according to RECIST v1.1 criteria. Colorectal eligibility wording from the registry: "* Participants with histologically and/or cytologically confirmed locally advanced/metastatic colorectal cancer". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07595276
- Phase: 3
- Setting: A Multicenter, Randomized, Double-blind, Phase III Clinical Study Evaluating the Efficacy and Safety of Enlituo® Plus FOLFOX Versus Erbitux® Plus FOLFOX as First-line Treatment for Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.
- Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd
- Enrolled: 608

## Sources

- ClinicalTrials.gov NCT07595276: https://clinicaltrials.gov/study/NCT07595276

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07595276.json